Isorhapontigenin

Idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease, is predominantly driven by oxidative stress-induced alveolar epithelial cell (AEC) senescence. However, effective therapeutic strategies for IPF remain rudimentary. Here, we demonstrate that isorhapontigenin (ISO), a compound known to mitigate oxidative damage and mitochondrial lipid peroxidation, attenuates pulmonary fibrosis by targeting peroxiredoxin 2 (PRDX2). Utilizing bleomycin-induced murine models and TGF-β-treated BEAS-2B cells, we demonstrated that ISO markedly attenuate histopathological alterations and extracellular matrix deposition associated with pulmonary fibrosis, while concurrently mitigating alveolar epithelial cell senescence. Integrative analyses combining network pharmacology and proteomics identified PRDX2 as a principal molecular target of ISO. Further molecular docking studies and drug affinity responsive target stability (DARTS) assays revealed that ISO engages PRDX2 through STAT3, establishing a key molecular bridge for their interaction. Notably, LC-MS/MS-based proteomics combined with single-cell sequencing further revealed a pronounced downregulation of PRDX2 expression in fibrotic lung tissues. Knockdown of PRDX2 exacerbated fibrotic progression, underscoring its protective role in pulmonary homeostasis. Mechanistically, ISO alleviates oxidative stress and prevents AEC senescence through PRDX2 upregulation, thereby offering a novel therapeutic strategy for IPF. These findings not only establish PRDX2 as a pivotal regulator of pulmonary fibrosis but also highlight ISO as a promising therapeutic candidate for IPF treatment.